This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Climent, J. Articles by Martinez-Climent, J. A. Search for Related Content PubMed PubMed Citation Articles by Climent, J. Articles by Martinez-Climent, J. A.

Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer

¹ Division of Oncology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; ² Department of Hematology and Medical Oncology, Hospital Clinico, University of Valencia, Valencia, Spain; ³ UCSF Comprehensive Cancer Center, San Francisco, California; ⁴ Division of Biostatistics, University of California; ⁵ Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California; ⁶ Molecular Pathology Program, National Center for Oncology Research, Madrid, Spain; and ⁷ Institute of Human Genetics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

Requests for reprints: Jose A. Martinez-Climent, Center for Applied Medical Research, Division of Oncology, University of Navarra, Avda. Pio XII, 55 31008 Pamplona, Spain. Phone: 34-948-194700, ext. 1029. Fax: 34-948-194714; E-mail: jamcliment{at}unav.es.

Despite the recent consensus on the eligibility of adjuvant systemic therapy in patients with lymph node–negative breast cancer (NNBC) based on clinicopathologic criteria, specific biological markers are needed to predict sensitivity to the different available therapeutic options. We examined the feasibility of developing a genomic predictor of chemotherapy response and recurrence risk in 185 patients with NNBC using assembled arrays containing 2,460 bacterial artificial chromosome clones for scanning the genome for DNA copy number changes. After surgery, 90 patients received anthracycline-based chemotherapy, whereas 95 did not. Tamoxifen was administered to patients with hormone receptor–positive tumors. The association of genomic and clinicopathologic data and outcome was computed using Cox proportional hazard models and multiple testing adjustment procedures. Analysis of NNBC genomes revealed a common genomic signature. Specific DNA copy number aberrations were associated with hormonal receptor status, but not with other clinicopathologic variables. In patients treated with chemotherapy, none of the genomic changes were significantly correlated with recurrence. In patients not receiving chemotherapy, deletion of eight bacterial artificial chromosome clones clustered to chromosome 11q was independently associated with relapse (disease-free survival at 10 years ± SE, 40% ± 14% versus 86% ± 6%; P < 0.0001). The 54 patients with deletion of 11q (29%) did not present more aggressive clinicopathologic features than those without 11q loss. The adverse influence of 11q deletion on clinical outcome was confirmed in an independent validation series of 88 patients with NNBC. Our data suggests that patients with NNBC with the 11q deletion might benefit from anthracycline-based chemotherapy despite other clinical, pathologic, or genetic features. However, these initial findings should be evaluated in randomized clinical trials. [Cancer Res 2007;67(2):818–26]

This article has been cited by other articles:

				M. Campos, C. Prior, F. Warleta, I. Zudaire, J. Ruiz-Mora, R. Catena, A. Calvo, and J. J. Gaforio Phenotypic and Genetic Characterization of Circulating Tumor Cells by Combining Immunomagnetic Selection and FICTION Techniques J. Histochem. Cytochem., July 1, 2008; 56(7): 667 - 675. [Abstract] [Full Text] [PDF]

				O. Kovalchuk, J. Filkowski, J. Meservy, Y. Ilnytskyy, V. P. Tryndyak, V. F. Chekhun, and I. P. Pogribny Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin Mol. Cancer Ther., July 1, 2008; 7(7): 2152 - 2159. [Abstract] [Full Text] [PDF]